In a prospective series by Sequist et al., 14% of patients (5 out of 37) demonstrated SCLC transformation while retaining their original EGFR mutation (L858R or exon 19 deletions) after progression on erlotinib [14]. The gene discussed is EGFR; the disease is small cell lung carcinoma.